Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity.
J Pediatr Hematol Oncol
; 38(2): 147-51, 2016 Mar.
Article
de En
| MEDLINE
| ID: mdl-26808368
ABSTRACT
6-Mercaptopurine (6-MP) is the mainstay of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma. It is metabolized into the pharmacologically active, 6-thioguanine nucleotide (6-TGN), and 6-methyl mercaptopurine nucleotides (6-MMPN), which is associated with hepatotoxicity that jeopardizes antileukemic therapy. Allopurinol alters the metabolism of 6-MP to increase 6-TGN levels and decreases 6-methyl mercaptopurine nucleotides levels. We report 2 cases in which combination therapy of allopurinol with 6-MP was used successfully to avoid hepatotoxicity while delivering adequate 6-TGN levels. We suggest that this combination therapy can be used safely to change the metabolite production in patients who develop excessive hepatotoxicity.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Allopurinol
/
Leucémie-lymphome lymphoblastique à précurseurs B et T
/
Mercaptopurine
/
Antimétabolites
/
Antimétabolites antinéoplasiques
Limites:
Adolescent
/
Child
/
Humans
/
Male
Langue:
En
Journal:
J Pediatr Hematol Oncol
Sujet du journal:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Année:
2016
Type de document:
Article
Pays d'affiliation:
Moldavie